Page 1

SCIBASE INTERIM REPORT JANUARY - JUNE 2021 Interim report January 1 - June 30 , 2021 The second quarter in figures Net sales amounted to TSEK 2,258 [ 1,683 ) . The loss after tax amounted to TSEK 11,151 ( 8,864 ) . The loss per share amounted to SEK 0.19 ( 0.38 ) . The cash flow from current operations was negative in the amount of TSEK 9,162 ( 8,704 ) . The gross margin reached 56.3 % ( 55.7 % ) . Electrode sales volume increased by 28 % and reached 5,968 ( 4,672 ) units . Repeat sales of elec trodes to existing customers increased by 23 % . January - June in figures Net sales amounted to TSEK 4,821 [ 4,179 ) . The loss after tax amounted to TSEK 19,304 ( 17,800 ) . The loss per share amounted to SEK 0.34 ( 0.89 ) . The cash flow from current operations was negative in the amount of TSEK 18,635 [ 16,597 ) . • The gross margin reached 54.4 % [ 54.7 % ) . Electrode sales volume increased by 19 % and reached 13,464 ( 11,270 ) units . Repeat sales of electrodes to existing customers increased by 20 % . Important events during the quarter Overall sales increased by 34 % ( cleared for cur rency effects + 43 % ) . Covid - 19 continues to affect sales and the market situation remains difficult to predict going forward , due to ongoing lockdowns and reduced marketing activities . Sales in the com pany's key market Germany increased by 13 % [ cleared for currency effects + 19 % ) . SciBase performed two successful directed share issues which raised approximately MSEK 66.5 net , after issue costs . SciBase submitted the first US reimbursement ap plication to CMS's Medicare Contractor in Florida , First Coast Service Options ( FCSO ) . The application for Medicare coverage in Florida marks an im portant step in the reimbursement process for Sci Base and is a necessary step towards broader pene tration and usage of the Nevisense test . SciBase received certification under the new Medi cal Device Regulation ( MDR ) . The new Non - Melanoma Skin Cancer ( NMSC ) clini cal application was launched following the comple tion of the MDR certification process . SCIBASE A groundbreaking article by key SciBase collabora tor Professor Cezmi Akdis presenting the " epithelial barrier hypothesis " was published in Nature Reviews Immunology . The article presented the background for the steep increase in allergic and other diseases over the last decades , and how this increase is con nected to degradation in barrier function in the body . The notice to attend the AGM 2021 was published as well as the nominating committees supplemen tary proposal to nominate Dr Matt Leavitt for the Board of Directors . r 1 A new clinical study from the Swiss Institute of Al lergy and Asthma Research ( SIAF ) was published in the European Journal of Allergy and Clinical Immu nology ( Allergy ) . In the study Nevisense was used to assess the skin barrier of patients with atopic der matitis ( AD ) and could accurately detect signs of barrier degradation in atopic patients , even in visu ally unaffected skin . Nevisense measurements also correlated with relevant biomarkers for atopic der matitis . The AGM 2021 was held on May 18 . An EGM was held on June 16th . The annual report 2020 was published on April 9th Important events after the end of the period SciBase has entered into an agreement with Vator Securities AB ( " Vator Securities " ) regarding the ser vice as a Certified Adviser . Vator Securities will take over as Certified Adviser on September 28 , 2021 . Until Vator Securities takes over , Avanza Bank AB will continue to act as Certified Adviser for the Company .